Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Geethanjali R"'
Autor:
Geethanjali, R.1 (AUTHOR) geethanjaliyokesh18@gmail.com, Valarmathi, A.2 (AUTHOR)
Publikováno v:
Scientific Reports. 9/30/2024, Vol. 14 Issue 1, p1-27. 27p.
Autor:
Geethanjali, R., Krishnamurthy, Madhuram, Natanasabapathy, Velmurugan, Kumar, V. Naveen, Leburu, Ashok, Elangovan, Selvendran Kasiswamy
Publikováno v:
Journal of Conservative Dentistry & Endodontics; May2024, Vol. 27 Issue 5, p552-555, 4p
Publikováno v:
Biomedicine. 43:582-586
Introduction and Aim: The number of patients suffering from end stage renal disease (ESRD) requiring dialysis has increased worldwide. Mineral bone disorders (MBD) commonly occur in ESRD patients. MBD is classified into high turnover bone disease and
Publikováno v:
In Materials Today: Proceedings 2018 5(8) Part 3:16246-16257
Autor:
Geethanjali, R., Subhashini, S.
Publikováno v:
In Chinese Journal of Chemical Engineering April 2016 24(4):543-552
Publikováno v:
2023 IEEE 8th International Conference for Convergence in Technology (I2CT).
Autor:
Supriya M S, Sahana P Shankar, Sodum Sai Mohan Reddy, Geethanjali R, Sathvika S, Sona Shetty R
Publikováno v:
2022 4th International Conference on Circuits, Control, Communication and Computing (I4C).
Publikováno v:
International Ayurvedic Medical Journal. 9:1425-1432
Some of the medicinal plants valued in Ayurvedic Rasayana for their therapeutic potential have seen scientifically investigated with promising results. Several plant-based principles have been isolated with a potential immunomod- ulatory activity tha
Publikováno v:
International Journal of Research in Engineering, Science and Management; Vol. 5 No. 6 (2022); 127-131
Water is essential for all living organisms and economic growth, social progress, environmental integrity. Nowadays, an increase in the development of smart water cadence trials and demand operation requires advanced spatial and temporal opinions. Th
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract In oncology anti—PD1 / PDL1 therapy development for solid tumors, objective response rate (ORR) is commonly used clinical endpoint for early phase study decision making, while progression free survival (PFS) and overall survival (OS) are w
Externí odkaz:
https://doaj.org/article/2fcb5d71d6c540c39d5d70e19e351802